Clinical Trial Search

Primary: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value — 96.6; 100; 0; 91.3 percentage

Primary: Difference in Pain Score as Measured by a Visual Analogue Scale (VAS) — 26.4; 43.0 Units on a 100 mm VAS — p=0.0311

Primary: The Percentage Change in HbF Level From Baseline to the Average Over the Final 1 Month of Study. — 1; 1; 6 Participants

Primary: Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More — 21; 10 Participants

Primary: Measurement of Time Average Mean of the Maximum (TAMM) in cm/Sec in Cerebral Arteries Using 2 Different Ultrasound Machines. — 120; 120 cm/sec

Primary: Mean Red Blood Cells Lifespan in Participants — 64.1; 113.4; 126.0; 123.7 day — p=<0.001

Primary: Number of Participants Who Completed Follow up — 35; 17 Participants

Primary: Change (T1 - T5) From Baseline in Scores on the Sickle Cell Self-Efficacy Scale (SCSES) — -1.73 score on a scale

Primary: Pain Rating Using Visual Analog Scale at Day 1 and Day 5 — 40.5; 45.8; 30.3; 38.5 score on a scale

Primary: Number Participants With Most Common Reported Drug Related Adverse Events — 6; 3; 3 Participants

Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change

Primary: SS RBC Adhesion (Epi -1d/cm2- vs. Sham) by Treatment — 0; -0.3; 7.4; 2.7 Percentage of total RBC

Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT

Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants

Primary: Level of Satisfaction on SCD Current Treatment and Management — 4.12 score on a scale